Chris Booth
CEO
FD
FYR Diagnostics
FYR Diagnostics develops liquid biopsy solutions utilizing Extracellular Vesicles (EVs) to provide accurate and efficient biomarker detection for chronic diseases in human healthcare and agriculture. Their technology addresses the need for reliable diagnostics by offering high-quality sample-to-analysis sequencing services in a CLIA-certified laboratory.
- Artificial Intelligence
- Data & Analytics
- Biotechnology
- Healthcare Technology
Updated 5 months ago
Funding
Raised to date
$8.7MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Traditional diagnostic methods for chronic diseases often rely on invasive surgical biopsies, which pose risks to patients and may not always provide a comprehensive molecular snapshot of the disease. Detecting diseases early and monitoring their progression requires less invasive and more informative techniques.
Solution
FYR Diagnostics offers liquid biopsy solutions that utilize Extracellular Vesicles (EVs) to provide accurate biomarker detection for chronic diseases. Their EVO-Platform leverages multi-omics analysis, including genomics, transcriptomics, and proteomics, to unlock the potential of EVs and provide a detailed molecular snapshot of the disease from a simple blood draw. The company's proprietary SPARCs technology isolates disease-associated EV subpopulations, enriching for relevant biomarkers and improving the signal-to-noise ratio. FYR's CLIA-certified laboratory provides high-quality sample-to-analysis sequencing services, enabling better patient stratification, more detailed disease insights, and earlier disease detection.
Target Audience
FYR Diagnostics serves researchers, pharmaceutical companies, and healthcare providers focused on advancing targeted therapies, designing biomarker-driven trials, and developing precision diagnostics.
Features
- Proprietary SPARCs technology for selective isolation of disease-associated EV subpopulations
- EVO-Platform for multi-omics analysis of EVs, including genomics, transcriptomics, and proteomics
- AI-enabled data analysis and machine learning models for data-driven decisions
- CLIA-certified laboratory for high-quality sample-to-analysis sequencing services
- Minimally invasive liquid biopsies using blood samples
- Biomarker discovery and validation for early disease detection and monitoring
- Support for diagnostic test development and deployment
- Custom data outputs and flexible engagement models for partners